CSIMarket Company Name, Ticker, Customers, else..
 
Apollomics Inc   (NASDAQ: APLM)
 
Price: $27.4950 $-0.51 -1.839%
Day's High: $27.4950008392334 Week Perf: 1.5 %
Day's Low: $ 27.50 30 Day Perf: 61.74 %
Volume (M): 1,507 52 Wk High: $ 42.12
Volume (M$): $ 0 52 Wk Avg: $17.97
Open: $27.50 52 Wk Low: $5.20



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) -
 Employees 20
 Revenues (TTM) (Millions $) 9
 Net Income (TTM) (Millions $) -11
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Business Description


The company is a development-stage biotechnology firm engaged in drug discovery, preclinical studies, and clinical trials of product candidates. It currently has no approved products or revenue from sales. Its most advanced product candidate is vebreltinib, which requires further clinical development and regulatory approval prior to commercialization. The company collaborates with partners such as LaunXP for development and commercialization activities and may pursue additional capital or partnerships to support its operations.


   Company Address: 989 E. Hillsdale Blvd., Suite 220 Foster City 94404 CA
   Company Phone Number: 209-4055   Stock Exchange / Ticker: NASDAQ APLM


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Product Service News

Navigating Market Challenges Apollomics, Inc. Operational Update and Share Performance Analysis

Published Tue, Oct 14 2025 7:55 AM UTC

In a recent operational update issued on October 13, 2025, Apollomics, Inc. (Nasdaq: APLM) provided insights into its current corporate standing amidst fluctuating market conditions. The announcement, while affirming the company s operational continuity, has taken place during a period where its share performance appears to be lagging behind broader market trends.Apollomics,...
Clinical Study

Efficacy and Strategic Directions in Oncology Recent Developments from Apollomics

Published Fri, Dec 20 2024 1:00 PM UTC

Navigating the Complex Landscape of Relapsed Acute Myeloid Leukemia and MET-Fusion Solid Tumors: Insights from Apollomics’ Latest Trials In the realm of oncology, the quest for effective treatments for particularly challenging malignancies remains a paramount focus for clinical researchers and biopharmaceutical companies. Recent announcements from Apollomics Inc. a late-st...
Shares

Apollomics Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split

Published Thu, Nov 21 2024 1:00 PM UTC

Apollomics Announces Reverse Share Split: A Strategic Move ForwardOn September 16, 2024, Apollomics, a company pioneering advancements in the field of oncology, made an important announcement concerning its capital structure: the approval of a 1-for-100 reverse share split. This highly significant corporate action, which aligns with the company s strategic objectives, is se...
Clinical Study

Observations on the Efficacy of Vebreltinib in Patients with Non-Small Cell Lung Cancer Exhibiting METex14 Skipping M...

Published Mon, Sep 16 2024 12:01 PM UTC

In this esteemed publication, we take the liberty of presenting findings that emanated from a notable assembly, the European Society for Medical Oncology (ESMO) Congress of the year 2024, where Apollomics revealed significant data concerning Vebreltinib a novel therapeutic agent under examination for its utility in cases of non-small cell lung cancer (NSCLC) harbouring MET...
Clinical Study

Apollomics Announces Strategic Focus on Vebreltinib Study Enrollment for NSCLC Patients with Met Amplification Mutations

Published Wed, Jul 3 2024 12:00 PM UTC

Apollomics, a biopharmaceutical company, recently unveiled its updated strategic focus, emphasizing the enrollment of non-small cell lung cancer (NSCLC) patients with Met Amplification mutations in the vebreltinib study. This new direction aims to address the significant unmet medical need for effective treatment options targeting this specific mutation.Background:Met Amplif...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.52
Working Capital Ratio 0.96
Leverage Ratio (MRQ) -
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) 0 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash -
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 425,000
Net Income per Employee (TTM) -546,950
Receivable Turnover Ratio (TTM) 3.69
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 1.27

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) 165.07 %
Net Margin (MRQ) -128.69 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Apollomics Inc's Segments





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.